<DOC>
	<DOCNO>NCT01017575</DOCNO>
	<brief_summary>The purpose study identify least 1 dose Daclatasvir , combine peginterferon-alfa ( PegIFNα ) ribavirin ( RBV ) treatment chronically infect HCV genotype 1 treatment-naïve non-responder standard care subject safe , well tolerate , efficacious</brief_summary>
	<brief_title>Safety Efficacy Daclatasvir ( BMS-790052 ) Plus Standard Care Japanese Patients ( Pegylated-interferon Alpha-2a Ribavirin )</brief_title>
	<detailed_description />
	<mesh_term>Infection</mesh_term>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<mesh_term>Peginterferon alfa-2a</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<criteria>Key Subjects chronically infect hepatitis C virus ( HCV ) genotype 1 HCV RNA viral load ≥ 10*5* IU/mL ( 100,000 IU/mL ) screen The current standard care naïve nonresponder Key Cirrhosis HCC Coinfection hepatitis B virus ( HBV ) , HIV1 HIV2</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>August 2015</verification_date>
</DOC>